Epidermal Langerhans cell density in patients with pulmonary malignancies and chronic obstructive pulmonary disease.
To evaluate the relationship between ELC density and pulmonary malignancies, as reported in previous investigations, we examined the nonsun-exposed epidermis of 18 patients with pulmonary cancer (CA) not receiving immunosuppressive therapy, 20 patients with chronic obstructive pulmonary disease (COPD-S), and 10 patients with COPD receiving glucocorticosteroid (GCS) therapy (COPD + S). The ELC density was not significantly different between lung tumor patients (1024 +/- 167) and COPD-S (1072 +/- 200, p less than 0.4) control patients, and we found no significant correlation between ELC density and tumor cell type, presence or absence of metastases, tumor stage, or present smoking status. Although we did detect that systemic GCS therapy significantly reduced the ELC density in COPD + S patients (910 +/- 211, p less than 0.05); use of inhaled or chronic low dose (less than or equal to 20 mg daily) GCS did not appear to significantly alter ELC density. In addition, anergy to epicutaneous dinitrochlorobenzene in CA and COPD + S patients positively correlated with a reduction in ELC density, suggesting a possible functional deficit arising from the numerical change. Further investigation is needed to elucidate whether factor(s) other than a reduction in ELC density are involved in the anergic state.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002452:Cell Count; D004137:Dinitrochlorobenzene; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007801:Langerhans Cells / Q000473:pathology*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000473:pathology*; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012882:Skin Tests; D012907:Smoking
D004137:Dinitrochlorobenzene; D005938:Glucocorticoids